Market Place
Sourcing Support
Merck mystified by sudden `step down` in Gardasil sales in China
30 Jul 2024 //
FIERCE PHARMA
Merck aims to `outnumber` pulmonary arterial hypertension
16 Apr 2024 //
FIERCE PHARMA
Merck`s Biologic Winrevair (sotatercept) Receives Approval in U.S
27 Mar 2024 //
FDA
US FDA approves Merck`s therapy for rare lung condition
27 Mar 2024 //
REUTERS
Merck Presents New Analyses Supporting the Promising Potential of Sotatercept
11 Sep 2023 //
BUSINESSWIRE
Merck unwraps full PIII data on the centerpiece from its $11.5B Acceleron buyout
07 Mar 2023 //
ENDPTS
Merck cardio plan forms as sotatercept, PCSK9 inhibitor impress
06 Mar 2023 //
FIERCE BIOTECH
Merck`s drug boosts exercise capacity in pulmonary hypertension
06 Mar 2023 //
BUSINESSWIRE
Merck to Present New Data for Sotatercept and MK-0616 at ACC.23/WCC
21 Feb 2023 //
BUSINESSWIRE
Is Merck Moving Toward Another Blockbuster Drug Launch?
26 Oct 2022 //
FOOL
Merck nails phase 3 sotatercept win a year after acquiring it
11 Oct 2022 //
FIERCEBIOTECH
Merck`s reported $11B Acceleron buy could face antitrust hurdles
28 Sep 2021 //
FIERCEPHARMA
Merck emerges as lead bidder in potential Acceleron buyout — report
27 Sep 2021 //
ENDPTS
Mystery suitor lines up $11B Acceleron acquisition: report
27 Sep 2021 //
FIERCEBIOTECH
Acceleron Receives Orphan Designation from the (EC) for Sotatercept
14 Dec 2020 //
BUSINESSWIRE
Acceleron Receives Orphan Designation from the (EC) for Sotatercept
14 Dec 2020 //
BUSINESSWIRE
Acceleron Announces Clinical Trial Updates, Preclinical on Sotatercept
09 Nov 2020 //
BIOSPACE
Acceleron to Host Conference Call & Webcast to Review Ph2 Trial of Sotatercept
22 Jun 2020 //
BUSINESSWIRE
Acceleron Announces Publication in Science Translational Medicine Sotatercept
13 May 2020 //
BUSINESSWIRE
Acceleron Completes Target Enrollment in the PULSAR Phase 2 Trial of Sotatercept
26 Jun 2019 //
BIOSPACE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.